Tandem Diabetes Care (TNDM) Raised to Strong-Buy at BidaskClub

Tandem Diabetes Care (NASDAQ:TNDM) was upgraded by BidaskClub from a “buy” rating to a “strong-buy” rating in a note issued to investors on Saturday.

Several other equities research analysts also recently issued reports on TNDM. Lake Street Capital set a $60.00 price objective on Tandem Diabetes Care and gave the stock a “buy” rating in a research note on Saturday, November 3rd. Craig Hallum set a $59.00 target price on Tandem Diabetes Care and gave the stock a “buy” rating in a research report on Friday, November 2nd. UBS Group initiated coverage on Tandem Diabetes Care in a research report on Tuesday, November 27th. They issued a “neutral” rating and a $36.00 target price on the stock. Zacks Investment Research lowered Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research report on Saturday, October 6th. Finally, Oppenheimer set a $57.00 target price on Tandem Diabetes Care and gave the stock a “buy” rating in a research report on Friday, November 9th. Four investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $44.75.

Shares of Tandem Diabetes Care stock opened at $42.50 on Friday. The stock has a market capitalization of $2.33 billion, a P/E ratio of -3.30 and a beta of 0.36. Tandem Diabetes Care has a 1 year low of $2.14 and a 1 year high of $52.55.



Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Thursday, November 1st. The medical device company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.28). The business had revenue of $46.30 million during the quarter, compared to analysts’ expectations of $42.71 million. Tandem Diabetes Care had a negative return on equity of 204.32% and a negative net margin of 93.07%. The firm’s revenue was up 71.5% on a year-over-year basis. During the same period in the prior year, the company posted ($3.09) earnings per share. As a group, analysts predict that Tandem Diabetes Care will post -1.31 earnings per share for the current year.

In other Tandem Diabetes Care news, CEO Kim D. Blickenstaff sold 198,000 shares of the company’s stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $37.01, for a total value of $7,327,980.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP David B. Berger sold 11,493 shares of the company’s stock in a transaction dated Thursday, December 6th. The stock was sold at an average price of $34.54, for a total value of $396,968.22. Following the completion of the transaction, the executive vice president now directly owns 11,765 shares in the company, valued at $406,363.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 265,281 shares of company stock worth $9,812,877. Insiders own 9.30% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Rhumbline Advisers acquired a new position in shares of Tandem Diabetes Care during the 2nd quarter valued at about $943,000. Prudential Financial Inc. acquired a new position in shares of Tandem Diabetes Care during the 3rd quarter valued at about $235,000. Fox Run Management L.L.C. acquired a new position in shares of Tandem Diabetes Care during the 3rd quarter valued at about $203,000. Voya Investment Management LLC acquired a new position in shares of Tandem Diabetes Care during the 2nd quarter valued at about $386,000. Finally, Macquarie Group Ltd. acquired a new position in shares of Tandem Diabetes Care during the 2nd quarter valued at about $423,000. 71.60% of the stock is currently owned by institutional investors and hedge funds.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured Article: What is a back-end load?

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply